We’re not immune to publicity: Keep up with our story below

MiroBio is committed to scientific and industry engagement in pursuit of our vision for a new approach to autoimmune disease therapies. Below you can review our news and other updates for our network.

Press Release

August 4, 2022


Acquisition Provides Gilead with MiroBio’s Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform MiroBio’s Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases Complements Gilead’s Inflammation…

June 29, 2022

MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases

Financing led by Medicxi with significant participation from new and existing shareholders Lead program MB272 targeting checkpoint receptor BTLA, entering Phase I clinical trials Funds will be used to advance…

March 8, 2022

MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease

Sanjay Keswani, MBBS, FRCP to join company as Chief Medical Officer bringing extensive experience in drug development and life sciences leadership Lynne Murray, Ph.D., MBA appointed as Chief Scientific Officer…

October 7, 2019

MiroBio launches with £27m ($34m) Series A from leading life sciences investors

Oxford start-up developing novel therapeutics based on deep expertise in immune cell regulation Oxford, UK, October 7 2019 – MiroBio, a novel therapeutics company based on insights into the regulation…

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser